Marisa Miceli, MD
Infectious Disease · Ann Arbor, MINPI 1366635971
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,787 of the $19,104 with a category attached, or 61.7%. GSK accounts for 63.9% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $12,199, 8.5 times the $1,439 reported in 2019. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $1123.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- Astellas Pharma Global Development$5K
- Astellas Pharma US Inc$2K
- Scynexis, Inc.$93
- Melinta Therapeutics, LLC$61
- Mayne Pharma Commercial LLC$33
Across 44 payments — averaging $11,965 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$369K
- Scynexis, Inc.$111K
- Mayne Pharma Commercial LLC$47K
What the payments were for
- Consulting fees$7,13137%
- Travel & lodging$11,78762%
- Food & beverage$1251%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $12,199 |
| Astellas Pharma Global Development | 3 | $4,880 |
| Astellas Pharma US Inc | 8 | $1,839 |
| Scynexis, Inc. | 2 | $93 |
| Melinta Therapeutics, LLC | 1 | $61 |
| Mayne Pharma Commercial LLC | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRESEMBA$6,719
How this compares
$19,104 in reported general payments places this provider in the 90th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $174,701 |
| Daptomycin | 22 | $30,874 |
| ErtapenemErtapenem Sodium | 22 | $9,772 |
| Vancomycin Hcl | 37 | $6,733 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $1,448 |
| Cephalexin | 26 | $395 |
| Cefazolin Sodium | 14 | $283 |
| CeftriaxoneCeftriaxone Sodium | 14 | $270 |
| Doxycycline Hyclate | 12 | $241 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Ann Arbor
- Keith KayeAnn Arbor$187K
- Owen AlbinAnn Arbor$25K
- David MarkovitzAnn Arbor$24K
- Payal PatelAnn Arbor$23K
- Adam LauringAnn Arbor$7K
- Krishna RaoAnn Arbor$3K
- Laraine WasherAnn Arbor$3K
- Suzanne BradleyAnn Arbor$2K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.